PharmaEngine, Inc. (TPEX:4162)
Taiwan
· Delayed Price · Currency is TWD 68.40
-1.70 (-2.43%)
Aug 15, 2025, 1:30 PM CST
PharmaEngine Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 2,481 | 2,523 | 767.67 | 654.38 | 654.84 | 1,056 | Upgrade
|
| Revenue Growth (YoY) | 188.62% | 228.70% | 17.31% | -0.07% | -37.99% | 236.27% | Upgrade
|
| Cost of Revenue | 48.34 | 47.74 | 48.7 | 49.7 | 37.07 | 37.23 | Upgrade
|
| Gross Profit | 2,433 | 2,476 | 718.97 | 604.68 | 617.76 | 1,019 | Upgrade
|
| Selling, General & Admin | 153.6 | 155.37 | 131.51 | 140.06 | 118.4 | 113.35 | Upgrade
|
| Research & Development | 250.33 | 267.03 | 310.28 | 181.88 | 136.89 | 95.73 | Upgrade
|
| Operating Expenses | 403.92 | 422.4 | 441.79 | 321.95 | 255.07 | 209.07 | Upgrade
|
| Operating Income | 2,029 | 2,053 | 277.18 | 282.74 | 362.69 | 809.71 | Upgrade
|
| Interest Expense | -0.12 | -0.18 | -0.31 | -0.08 | -0.21 | -0.44 | Upgrade
|
| Interest & Investment Income | 86.17 | 72.14 | 54.32 | 25.57 | 15.42 | 41.61 | Upgrade
|
| Currency Exchange Gain (Loss) | 37.66 | 37.66 | -2.13 | 8.8 | -15.68 | -107.06 | Upgrade
|
| Other Non Operating Income (Expenses) | -89.71 | - | - | 0.03 | 0.31 | 8.66 | Upgrade
|
| EBT Excluding Unusual Items | 2,063 | 2,163 | 329.06 | 317.06 | 362.53 | 752.48 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | 5.53 | 45.46 | 0.82 | - | Upgrade
|
| Other Unusual Items | 0.21 | 0.21 | 3.39 | 29.95 | 182.04 | - | Upgrade
|
| Pretax Income | 2,063 | 2,163 | 337.97 | 392.47 | 545.4 | 752.48 | Upgrade
|
| Income Tax Expense | 432.52 | 411.97 | 63.32 | 73.68 | 119.36 | 148.19 | Upgrade
|
| Net Income | 1,631 | 1,751 | 274.65 | 318.78 | 426.03 | 604.28 | Upgrade
|
| Net Income to Common | 1,631 | 1,751 | 274.65 | 318.78 | 426.03 | 604.28 | Upgrade
|
| Net Income Growth | 354.50% | 537.55% | -13.84% | -25.17% | -29.50% | 1320.17% | Upgrade
|
| Shares Outstanding (Basic) | 144 | 144 | 144 | 144 | 145 | 146 | Upgrade
|
| Shares Outstanding (Diluted) | 144 | 144 | 144 | 144 | 145 | 146 | Upgrade
|
| Shares Change (YoY) | 0.33% | 0.13% | 0.03% | -0.72% | -0.80% | 0.11% | Upgrade
|
| EPS (Basic) | 11.36 | 12.19 | 1.91 | 2.22 | 2.95 | 4.15 | Upgrade
|
| EPS (Diluted) | 11.31 | 12.17 | 1.91 | 2.22 | 2.94 | 4.14 | Upgrade
|
| EPS Growth | 354.16% | 537.17% | -13.96% | -24.49% | -28.99% | 1327.59% | Upgrade
|
| Free Cash Flow | 1,744 | 455.92 | 256.56 | 198.57 | 929.44 | 64.77 | Upgrade
|
| Free Cash Flow Per Share | 12.09 | 3.17 | 1.78 | 1.38 | 6.42 | 0.44 | Upgrade
|
| Dividend Per Share | 6.000 | 6.000 | 1.500 | 2.000 | 2.700 | 2.500 | Upgrade
|
| Dividend Growth | 300.00% | 300.00% | -25.00% | -25.93% | 8.00% | 400.00% | Upgrade
|
| Gross Margin | 98.05% | 98.11% | 93.66% | 92.41% | 94.34% | 96.47% | Upgrade
|
| Operating Margin | 81.77% | 81.37% | 36.11% | 43.21% | 55.39% | 76.68% | Upgrade
|
| Profit Margin | 65.72% | 69.39% | 35.78% | 48.72% | 65.06% | 57.22% | Upgrade
|
| Free Cash Flow Margin | 70.29% | 18.07% | 33.42% | 30.34% | 141.94% | 6.13% | Upgrade
|
| EBITDA | 2,031 | 2,055 | 278.55 | 283.44 | 363.39 | 811.29 | Upgrade
|
| EBITDA Margin | 81.85% | 81.43% | 36.29% | 43.31% | 55.49% | 76.83% | Upgrade
|
| D&A For EBITDA | 1.9 | 1.65 | 1.37 | 0.71 | 0.7 | 1.58 | Upgrade
|
| EBIT | 2,029 | 2,053 | 277.18 | 282.74 | 362.69 | 809.71 | Upgrade
|
| EBIT Margin | 81.77% | 81.37% | 36.11% | 43.21% | 55.39% | 76.68% | Upgrade
|
| Effective Tax Rate | 20.96% | 19.05% | 18.74% | 18.77% | 21.89% | 19.69% | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.